Study identifier:MB102-003
ClinicalTrials.gov identifier:NCT00162305
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, placebo-controlled, randomized, multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of bms-512148 in diabetic subjects
Diabetes Mellitus, Type 2
Phase 2
No
BMS-512148, Placebo
All
47
Interventional
18 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb
The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
Location
Location
Fort Lauderdale, FL, United States, 33301
Location
Miami, FL, United States, 33169
Location
New Orleans, LA, United States, 70119
Location
Orlando, FL, United States, 32809
Location
San Antonio, TX, United States, 78229-3894
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 | Drug: BMS-512148 Capsules, Oral, 100 mg, Once daily, 14 days. Other Name: Dapagliflozin |
Active Comparator: 2 | Drug: BMS-512148 Capsules, Oral, 25 mg, Once daily, 14 days. Other Name: Dapagliflozin |
Active Comparator: 3 | Drug: BMS-512148 Capsules, Oral, 5 mg, Once daily, 14 days. Other Name: Dapagliflozin |
Placebo Comparator: 4 | Drug: Placebo Capsules, Oral, 0 mg, Once daily, 14 days. Other Name: Dapagliflozin |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.